Abstract
Amiodarone, one of the most widely prescribed antiarrhythmic drugs to treat both ventricular and supraventricular arrhythmias, has been identified as a candidate drug for use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present the rationale of using amiodarone in the COVID-19 scenario, as well as whether or not amiodarone administration represents a potential strategy to prevent SARS-CoV-2 infection, rather than simply used to treat patients already symptomatic and/or with severe coronavirus disease 2019 (COVID-19), based on current evidence.
MeSH terms
-
Amiodarone / pharmacology*
-
Angiotensin-Converting Enzyme 2
-
Anti-Arrhythmia Agents / pharmacology
-
Antiviral Agents / pharmacology
-
Arrhythmias, Cardiac* / drug therapy
-
Arrhythmias, Cardiac* / virology
-
Betacoronavirus* / drug effects
-
Betacoronavirus* / physiology
-
COVID-19
-
Coronavirus Infections* / drug therapy
-
Coronavirus Infections* / metabolism
-
Coronavirus Infections* / physiopathology
-
Coronavirus Infections* / prevention & control
-
Humans
-
Pandemics* / prevention & control
-
Peptidyl-Dipeptidase A / metabolism
-
Pneumonia, Viral* / drug therapy
-
Pneumonia, Viral* / metabolism
-
Pneumonia, Viral* / physiopathology
-
Pneumonia, Viral* / prevention & control
-
Risk Assessment
-
SARS-CoV-2
-
Treatment Outcome
-
Virus Internalization / drug effects
Substances
-
Anti-Arrhythmia Agents
-
Antiviral Agents
-
Peptidyl-Dipeptidase A
-
ACE2 protein, human
-
Angiotensin-Converting Enzyme 2
-
Amiodarone